Pharmafile Logo
Pharmafocus logo
Advanced Search

MabThera gains maintenance therapy licence

October 29, 2010
Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

News

Watson submits Crestor copycat

October 28, 2010
Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent

 Watson Pharmaceuticals is seeking to launch a generic version of  AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …

News

Rep’s shotgun request misfires

October 28, 2010
Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis

Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …

News
GlaxoSmitKline's headquarters

GSK makes record whistleblower payout

October 28, 2010
Manufacturing and Production Cheryl Eckard, FDA, GSK, GlaxoSmithKline, manufacturing compliance, whistle blower

GlaxoSmithKline has officially agreed to plead guilty to distributing adulterated drugs made at its now-closed facility in Cidra, Puerto Rico, …

News

Engaging the digital audience

October 28, 2010
Medical Communications Andy Bell, Huntsworth Health, Jon Clark, Talking Point, digital marketing, digital pharma

We live in exciting times. With the rise of social media, people are changing the way they consume information. As …

Feature

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010
Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …

News

Intercell appoints Staph Leavenworth Bakali

October 27, 2010
Research and Development Intercell, Staph Leavenworth Bakali, appointment, research and development

Austrian biotech company Intercell has appointed Staph Leavenworth Bakali as chief business officer. He will have key responsibilities for the …

Appointment

£600m confirmed for three year Cancer Drugs Fund

October 27, 2010
Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …

News

Contract research news in brief

October 27, 2010
Research and Development Almac, Kinaxo, MediData Solutions, Quintiles, Ricerca Biosciences, Southern Research Institute, Venn Life Sciences, biofocus, contract research

Our latest crop of contract research news includes updates from Quintiles, Venn Life Sciences, Medidata Solutions, Southern Research Institute, Ricerca …

News

Health outcomes – does anything else matter?

October 27, 2010
Research and Development Les Rose, evidence-based medicine, healthcare outcomes, randomised controlled trials

So the mould of British politics has been broken, and we now have a government with probably a broader range …

Feature

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010
Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …

News
Blog footer

Digital Pharma: UK’s online dementia mentors

October 26, 2010
Medical Communications Alzheimer's disease, Comprehensive Spending Review, Digital Pharma blog, dementia, patient education

The Department of Health is looking for hundreds of people to become online dementia mentors as part of it ongoing …

News

Sanofi moves teriflunomide into phase III MS trials

October 26, 2010
Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide

Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …

News
Hugh_Douglas

Hugh Douglas joins BioCision

October 26, 2010
Manufacturing and Production BioCision, Hugh Douglas, Lori Kunkel, Paul Nowak, appointment, manufacturing and production

BioCision has expanded its management team, appointing Hugh Douglas as chief operating officer and adding to its corporate advisory board. …

Appointment

Shared API inspections project gains traction

October 26, 2010
Manufacturing and Production API, EDQM, EMA, FDA, TGA, manufacturing compliance, pharma manufacturing, regulatory affairs, regulatory inspections

A three-way initiative between regulatory authorities in the EU, US and Australia on the inspection of facilities making active pharmaceutical …

News

Pharma manufacturing news in brief

October 26, 2010
Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing

This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …

News

Minister confirms NICE will be sidelined in drug evaluation

October 26, 2010
Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing

A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …

News

Conducting clinical trials in China

October 26, 2010
Research and Development China, Jim Wei, Medpace, clinical trials, clinical trials in Chaia, regulatory affairs

As industry pressure to conduct successful global clinical trials on time and on budget continue, tapping emerging global markets will …

Feature

Sowing into Good Ground: Using “personalized medicine” for optimal treatment value

October 26, 2010
Sales and Marketing Kinapse, White paper

As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …

Feature
White paper

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010
Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026